Amgen's latest immuno-oncology drug comes through in Phase II

Amgen's ($AMGN) new immuno-oncology treatment demonstrated promising efficacy in a midstage trial on a rare blood cancer. In Phase II, the antibody, marketed as Bincyto, spurred complete remission or complete remission with partial hematological recovery in "a clinically meaningful number of patients" with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), the company said, keeping details to itself until a later medical meeting. Blincyto, formerly blinatumomab, won a speedy approval this year to treat Philadelphia chromosome-negative ALL, and Amgen is working to expand the therapy's adoption. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.